October 18, 2019 — Medical diagnostic artificial intelligence (AI) company MaxQ AI announced that its Accipio intracranial hemorrhage (ICH) and stroke software will be integrated on Philips’ computed tomography (CT) systems. The integration of Accipio’s AI-powered solutions into Philips CT systems will support the detection of ICH to augment caregivers in identifying and prioritizing patients suffering from stroke, traumatic brain injury, head trauma and other life-threatening conditions.
MaxQ AI’s Accipio ICH and Stroke Platform utilizes deep learning technologies to analyze medical imaging data such as non-contrast head CT images. The results provide deep clinical insight and actionable data in minutes that will enable physicians across the world to make faster assessments in any location, at any time. Accipio Ix enables automatic identification and prioritization of non-contrast head CT images with suspected ICH. Accipio Ax provides automatic slice-level annotation of suspected ICH. Both Accipio Ix and Ax are U.S. Food and Drug Administration (FDA)-cleared and CE approved.
The Accipio platform will be available with new Philips CT systems and as an upgrade to previously installed Philips CT systems throughout U.S. and EU markets. The first deployments are expected to take place in 2020.
The integration with Philips is MaxQ AI’s second such agreement in 2019 following a similar deal with GE Healthcare in January. The company announced its first distribution agreement with Samsung NeuroLogica in November 2018, shortly after Accipio IX received FDA clearance.
MaxQ AI will be demonstrating the company’s full suite of Accipio solutions during the upcoming Radiological Society of North America (RSNA) 2019 Annual Meeting, Dec. 1-6 in Chicago. Accipio will also be on display at the Philips exhibit.